What are the side effects of molotinib/mometinib?

Momelotinib/ Momelotinib is a new anti-cancer drug mainly used to treat myelofibrosis. In its two major pre-market clinical studies, researchers observed some common side effects that require special attention during treatment.

Thrombocytopenia is one of the most common side effects of molotinib. Patients may experience a decrease in their platelet count after treatment, making them more susceptible to bleeding problems such as bruising under the skin or nosebleeds. The mechanism of this adverse reaction is related to molotinib's effect on the blood system, so doctors usually monitor patients' platelet levels regularly during medication.

Diarrhea is also a relatively frequent adverse reaction. Patients may experience varying degrees of diarrheal symptoms, which may affect their quality of life and lead to complications such as dehydration. Therefore, patients need to maintain good fluid intake while taking molotinib and promptly report any severe diarrhea symptoms to their doctor.

Bleeding, fatigue, and dizziness are also common side effects. The risk of bleeding is mainly related to thrombocytopenia, while fatigue and dizziness may result from the drug's effect on the overall physical state. Patients who experience persistent fatigue or dizziness should consult a medical professional as soon as possible.

In addition to the common side effects mentioned above, some new adverse events have emerged after molotinib was launched. For example, eye conditions such as blurred vision have emerged as a side effect reported by patients, affecting some patients' daily lives. At the same time, the incidence of infections has also increased, including fungal infections. These infections can put additional stress on the immune system, so doctors need to pay close attention to a patient's health during treatment.